Latest news

• Novartis sets sights on connected inhaler

  Novartis plans a 2019 launch for the new device, which will be available for its COPD portfolio of Onbrez, Breezhaler Seebri, and Ultibro Breezhaler.

• Novartis' combo COPD inhaler cleared in EU

  and Onbrez, respectively.

• Boehringer’s first cancer drug leads EMA recommendations

  The product, which is to be marketed as Xoterna Breezhaler in some countries, combines indacaterol - a long-acting beta-adrenergic agonist (LABA) present in Novartis' Onbrez - and glycopyrronium bromide - a

• Novartis parts with Eisai to go it alone with COPD drugs

  The companies have called time on their partnership, which covered Novartis' Onbrez, Seebri and QVA149, just over a year after it was signed. ... Novartis will now go it alone in promoting Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and

• Novartis' COPD drug Seebri cleared in EU and Japan

  Seebri (glycopyrronium bromide) has been approved as a once-daily inhaled treatment for adults with COPD, and will join Novartis' long-acting beta agonist Onbrez/Arcapta (indacaterol maleate) which is already ... Both Seebri and Onbrez are expected to